MassMutual Private Wealth & Trust
CLDX icon

MassMutual Private Wealth & Trust’s Celldex Therapeutics CLDX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$583 Hold
18
– – ﹤0.01% 2190
2026
Q2 		$670 Hold
18
– – ﹤0.01% 2238
2026
Q1 		$571 Buy
+18
New +$491 ﹤0.01% 2208

Other funds holding CLDX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

MassMutual Private Wealth & Trust's CLDX Position: Q3 2026 in Review

MassMutual Private Wealth & Trust held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 18 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

MassMutual Private Wealth & Trust first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $670 in Q2 2026. 85 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • MassMutual Private Wealth & Trust held 18 shares of Celldex Therapeutics worth $583 as of Q3 2026.
  • MassMutual Private Wealth & Trust left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q3 2026, its #2190 holding.
  • MassMutual Private Wealth & Trust first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • MassMutual Private Wealth & Trust's Celldex Therapeutics position peaked at $670 in Q2 2026.
  • 85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.